Teva Beats Q1 2026 Forecasts as AUSTEDO & UZEDY Surge — Acquires Emalex for $700M Tourette Drug

Teva buys Emalex for $700M to add a new Tourette drug. Strong sales growth led by key medicines; generics weaker but outlook solid.